Catyalyst Pharma (NASDAQ: CPRX) reported Q1 EPS of ($0.07), in-line with the analyst estimate of ($0.07).

Upcoming 2016 Milestones

• Collaboratively working with the FDA to finalize a regulatory path forward for Firdapse
• Initiate the confirmatory Phase 3 trial for Firdapse to treat Lambert-Eaton myasthenic syndrome (LEMS)
• Evaluate our operating plan once the path forward to refile an NDA for Firdapse is determined, with a goal of completing the development of Firdapse and refiling an NDA using our current financial resources
• Continue to identify and recruit patients for the ongoing study evaluating Firdapse in the treatment of patients with congenital myasthenic syndromes (CMS)
• Continue to support an investigator-sponsored study evaluating Firdapse for the treatment of MuSK antibody positive Myasthenia Gravis
• Ongoing development of generic equivalent of Sabril® (vigabatrin)
• Continue to evaluate the pharmacological properties of CPP-115, subject to the availability of funding

For earnings history and earnings-related data on Catyalyst Pharma (CPRX) click here.